DOCSLIB.ORG

Does C-C Motif Chemokine Ligand 2 (CCL2) Link Obesity to a Pro-Inflammatory State?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Does C-C Motif Chemokine Ligand 2 (CCL2) Link Obesity to a Pro-Inflammatory State? International Journal of Molecular Sciences Review Does C-C Motif Chemokine Ligand 2 (CCL2) Link Obesity to a Pro-Inflammatory State? Sebastian Dommel 1 and Matthias Blüher 1,2,* 1 Medical Department III—Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Germany Liebigstr. 20, 04103 Leipzig, Germany; [email protected] 2 Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG), Helmholtz Zentrum München, University of Leipzig and University Hospital Leipzig, 04103 Leipzig, Germany * Correspondence: [email protected]; Tel.: +49-341-9715984 Abstract: The mechanisms of how obesity contributes to the development of cardio-metabolic diseases are not entirely understood. Obesity is frequently associated with adipose tissue dysfunction, characterized by, e.g., adipocyte hypertrophy, ectopic fat accumulation, immune cell infiltration, and the altered secretion of adipokines. Factors secreted from adipose tissue may induce and/or maintain a local and systemic low-grade activation of the innate immune system. Attraction of macrophages into adipose tissue and altered crosstalk between macrophages, adipocytes, and other cells of adipose tissue are symptoms of metabolic inflammation. Among several secreted factors attracting immune cells to adipose tissue, chemotactic C-C motif chemokine ligand 2 (CCL2) (also described as monocyte chemoattractant protein-1 (MCP-1)) has been shown to play a crucial role in adipose tissue macrophage infiltration. In this review, we aimed to summarize and discuss the current knowledge on CCL2 with a focus on its role in linking obesity to cardio-metabolic diseases. Keywords: adipokine; adipose tissue; obesity; inflammation; chemokine Citation: Dommel, S.; Blüher, M. Does C-C Motif Chemokine Ligand 2 (CCL2) Link Obesity to a Pro-Inflammatory State?. Int. J. Mol. 1. Introduction Sci. 2021, 22, 1500. https://doi.org/ Accumulation of adipose tissue (AT) is the major symptom of obesity. Until about 10.3390/ijms22031500 25 years ago, AT was regarded as an energy storage organ that additionally acts as isolation for the inner organs [1]. Due to the discovery of its endocrine function in the late 1980s, Academic Editor: Maria our understanding of AT changed fundamentally [2]. Since then, hundreds of bioactive Gisella Cavallo components secreted by AT have been found [3,4]. Those AT-derived secretory factors Received: 1 December 2020 including leptin, adiponectin, adipsin, plasminogen activator inhibitor-1 (PAI1), comple- Accepted: 29 January 2021 α Published: 2 February 2021 ment components, or cytokines such as tumor necrosis factors (e.g., TNF- ) or chemokines (e.g., CCL2) have been described with the term “adipokines” [5]. biologically active molecules secreted from adipose tissue Publisher’s Note: MDPI stays neutral In 1999, Funahashi et al. defined “ ” with regard to jurisdictional claims in as “adipocytokines” [6]. However, this term is potentially misleading because it suggests published maps and institutional affil- that all AT-secreted substances are cytokines. While this is true for some AT-secreted iations. molecules (e.g., IL-6 or TNF-α), the majority is of non-cytokine origin. Although Trayhurn and Wood recommended to use the term “’adipokine’ [ ... ] to describe a protein that is secreted from [ ... ] adipocytes”, commonly all AT-produced and -secreted substances are named “adipokines”, independent of whether they are secreted primarily from adipocytes or other AT cell types [7]. Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. Adipokines are a heterogenous group of peptides including hormones, growth factors, This article is an open access article and cytokines which differ in their physiological functions. Adipokines play an important distributed under the terms and role in the regulation of energy homeostasis, appetite, satiety, lipid metabolism and glu- conditions of the Creative Commons cose homeostasis, blood pressure and vascular homeostasis, angiogenesis, and immune Attribution (CC BY) license (https:// response [8]. Whereas adipocyte-secreted adiponectin and leptin circulate in the blood creativecommons.org/licenses/by/ as endocrine factors, it was demonstrated that some adipokines mainly have a para or 4.0/). autocrine functions within AT without a contribution to inter-organ tissue crosstalk [9]. Int. J. Mol. Sci. 2021, 22, 1500. https://doi.org/10.3390/ijms22031500 https://www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2021, 22, 1500 2 of 20 Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 2 of 21 Serum concentrations of several adipokines reflect body energy stores, fat mass and dis- tribution, systemic insulin sensitivity, glucose tolerance, a pro-inflammatory state, and other phenotypeor autocrine characteristics functions within [4,10 AT–16 without]. As examples,a contribution leptin to inter-organ serum concentrations tissue crosstalk [9]. are proportionallySerum secreted concentrations to body of fatseveral mass adipokines [17], where reflect circulating body energy adiponectin stores, fat mass are and typically dis- lower in individualstribution, systemic with obesityinsulin sensitivity, compared gluc toose those tolerance, who a are pro-inflammatory lean [18]. Additionally, state, and several immune-modulatingother phenotype characteristics adipokines, [4,10–16]. such as As IL-6, examples, IL-8, CXCL5,leptin serum or CCL2, concentrations are elevated are in the obeseproportionally state [9,19]. secreted These changesto body fat in mass adipokines’ [17], where secretion circulating pattern adiponectin can beare explainedtypically lower in individuals with obesity compared to those who are lean [18]. Additionally, sev- by AT remodeling, a process in which quantitative and qualitive changes in the cellular eral immune-modulating adipokines, such as IL-6, IL-8, CXCL5, or CCL2, are elevated in compositionthe of obese AT occurstate [9,19]. in response These changes to excessive in adipok weightines’ secretion gain [20 pattern]. can be explained by AT is aAT complex remodeling, organ a process composed in which of severalquantitative cell and types qualitive (Figure changes1). Adipocytes in the cellular account com- for up to 80%position of AT of volume, AT occur but in response reflect onlyto excessive 20–40% weight of cell gain number. [20]. AT consists of adipose- derived stem cellsAT is (ADSCs), a complex preadipocytes, organ composed endothelialof several cell cells,types (Figure and leukocytes 1). Adipocytes [21, 22account]. Very recently, single-nucleusfor up to 80% of RNA-sequencing AT volume, but reflect (snRNA-seq) only 20–40% of analysis cell number. of mouse AT consists and of human adi- adipose tissuepose-derived revealed stem a subpopulation cells (ADSCs), preadipocytes, of adipocytes endothelial that regulates cells, and thermogenesis leukocytes [21,22]. [23 ]. Very recently, single-nucleus RNA-sequencing (snRNA-seq) analysis of mouse and hu- Dependingman on theiradipose type, tissue different revealed AT-cellsa subpopulation produce of adipocytes distinct adipokinethat regulates patterns. thermogenesis There- fore, knowing[23]. theDepending cellular on origin their fortype, adipokine different AT-c productionells produce is important distinct adipokine to dissect patterns. which cell type mightTherefore, be enriched knowing the and/or cellular activated origin for inad AT.ipokine For production example, is adipocytes important to exhibit dissect a quantitativelywhich distinct cell type adipokine might be enriched pattern and/or in the acti functionvated in AT. of For the example, fat-depot adipocytes (subcutaneous exhibit (sc) and viscerala quantitatively (vis)) origin. distinct Adiponectinadipokine pattern and in leptinthe function are predominantly of the fat-depot (subcutaneous expressed in sc AT [24].(sc) In contrast,and visceral IL-6 (vis)) [25 origin.], omentin Adiponectin [26], visfatinand leptin [27 are], andpredominantly RBP4 exhibit expressed higher in sc vis AT [24]. In contrast, IL-6 [25], omentin [26], visfatin [27], and RBP4 exhibit higher vis than than sc production [28]. Adipsin [29], lipocalin 2 [30], and TNF-α [31] are secreted in both sc production [28]. Adipsin [29], lipocalin 2 [30], and TNF-α [31] are secreted in both de- depots in comparablepots in comparable amounts. amounts. Using Using single-cell single-cell or singleor single nuclei nuclei transcriptomics, transcriptomics, it itis isnow now possible topossible discriminate to discriminate adipocyte adipocyte subpopulations subpopulatio withinns within one one depot, depot, as as wellwell as more more than than 10 different10 AT different cell types AT cell which types differwhich indiffer their in their metabolic metabolic and and transcriptional transcriptional properties properties including theincluding identification the identification of differences of differences in cellular in cellular adipokine adipokine sources sources [ 23[23,32–34].,32–34]. Figure 1. Adipose tissue cells secrete distinct adipokines. Adipose tissue consists of a variety of cell Figure 1. Adipose tissue cells secrete distinct adipokines. Adipose tissue consists of a variety of cell types, such as adipo- cytes, preadipocytes,types, such adipose as tissue-derived adipocytes, preadipocytes,stem cells, and several adipose immune tissue-derived cells which produce stem cells, and secrete and several cell-type- immune specific adipokines.cells which +/−, higher/lower produce andsecreted secrete in sc cell-type-specificor vis. c-KIT, KIT proto-oncogene,
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Bioinformatics Identification of CCL8/21 As Potential Prognostic
    Bioscience Reports (2020) 40 BSR20202042 https://doi.org/10.1042/BSR20202042 Research Article Bioinformatics identification of CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment 1,* 2,* 3 4 5 1 Bowen Chen , Shuyuan Zhang ,QiuyuLi, Shiting Wu ,HanHe and Jinbo Huang Downloaded from http://portlandpress.com/bioscirep/article-pdf/40/11/BSR20202042/897847/bsr-2020-2042.pdf by guest on 28 September 2021 1Department of Breast Disease, Maoming People’s Hospital, Maoming 525000, China; 2Department of Clinical Laboratory, Maoming People’s Hospital, Maoming 525000, China; 3Department of Emergency, Maoming People’s Hospital, Maoming 525000, China; 4Department of Oncology, Maoming People’s Hospital, Maoming 525000, China; 5Department of Medical Imaging, Maoming People’s Hospital, Maoming 525000, China Correspondence: Shuyuan Zhang ([email protected]) Background: Breast cancer (BC) is the most common malignancy among females world- wide. The tumor microenvironment usually prevents effective lymphocyte activation and infiltration, and suppresses infiltrating effector cells, leading to a failure of the host toreject the tumor. CC chemokines play a significant role in inflammation and infection. Methods: In our study, we analyzed the expression and survival data of CC chemokines in patients with BC using several bioinformatics analyses tools. Results: The mRNA expression of CCL2/3/4/5/7/8/11/17/19/20/22 was remark- ably increased while CCL14/21/23/28 was significantly down-regulated in BC tis- sues compared with normal tissues. Methylation could down-regulate expression of CCL2/5/15/17/19/20/22/23/24/25/26/27 in BC. Low expression of CCL3/4/23 was found to be associated with drug resistance in BC.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • PD-1 / PD-L1 Combination Therapies
    PD-1 / PD-L1 Combination Therapies Jacob Plieth & Edwin Elmhirst – May 2017 Foreword Sprinkling the immuno-oncology dust When in November 2015 EP Vantage published its first immuno- oncology analysis we identified 215 studies of anti-PD-1/PD-L1 projects combined with other approaches, and called this an important industry theme. It is a measure of how central combos have become that today, barely 18 months on, that total has been blown out of the water. No fewer than 765 studies involving combinations of PD-1 or PD-L1 assets are now listed on the Clinicaltrials.gov registry. This dazzling array owes much to the transformational nature of the data seen with the first wave of anti-PD-1/PD-L1 MAbs. It also indicates how central combinations will be in extending immuno-oncology beyond just a handful of cancers, and beyond certain patient subgroups. But the combo effort is as much about extending the reach of currently available drugs like Keytruda, Opdivo and Tecentriq as it is about making novel approaches viable by combining them with PD-1/PD-L1. On a standalone basis several of the industry’s novel oncology projects have underwhelmed. As data are generated it will therefore be vital for investors to tease out the effect of combinations beyond that of monotherapy, and it is doubtful whether the sprinkling of magic immuno-oncology dust will come to the rescue of substandard products. This is not stopping many companies, as the hundreds of combination studies identified here show. This report aims to quantify how many trials are ongoing with which assets and in which cancer indications, as well as suggesting reasons why some of the most popular approaches are being pursued.
    [Show full text]
  • The Chemokine System in Innate Immunity
    Downloaded from http://cshperspectives.cshlp.org/ on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press The Chemokine System in Innate Immunity Caroline L. Sokol and Andrew D. Luster Center for Immunology & Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114 Correspondence: [email protected] Chemokines are chemotactic cytokines that control the migration and positioning of immune cells in tissues and are critical for the function of the innate immune system. Chemokines control the release of innate immune cells from the bone marrow during homeostasis as well as in response to infection and inflammation. Theyalso recruit innate immune effectors out of the circulation and into the tissue where, in collaboration with other chemoattractants, they guide these cells to the very sites of tissue injury. Chemokine function is also critical for the positioning of innate immune sentinels in peripheral tissue and then, following innate immune activation, guiding these activated cells to the draining lymph node to initiate and imprint an adaptive immune response. In this review, we will highlight recent advances in understanding how chemokine function regulates the movement and positioning of innate immune cells at homeostasis and in response to acute inflammation, and then we will review how chemokine-mediated innate immune cell trafficking plays an essential role in linking the innate and adaptive immune responses. hemokines are chemotactic cytokines that with emphasis placed on its role in the innate Ccontrol cell migration and cell positioning immune system. throughout development, homeostasis, and in- flammation. The immune system, which is de- pendent on the coordinated migration of cells, CHEMOKINES AND CHEMOKINE RECEPTORS is particularly dependent on chemokines for its function.
    [Show full text]
  • Rescuing Functional T Cells Induced by Growth Factor Deprivation, CCL2 Inhibits the Apoptosis Program
    CCL2 Inhibits the Apoptosis Program Induced by Growth Factor Deprivation, Rescuing Functional T Cells This information is current as Eva Diaz-Guerra, Rolando Vernal, M. Julieta del Prete, of September 24, 2021. Augusto Silva and Jose A. Garcia-Sanz J Immunol 2007; 179:7352-7357; ; doi: 10.4049/jimmunol.179.11.7352 http://www.jimmunol.org/content/179/11/7352 Downloaded from References This article cites 41 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/179/11/7352.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 24, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology CCL2 Inhibits the Apoptosis Program Induced by Growth Factor Deprivation, Rescuing Functional T Cells1 Eva Diaz-Guerra,2 Rolando Vernal,2 M. Julieta del Prete,2 Augusto Silva, and Jose A. Garcia-Sanz3 The precise mechanisms involved in the switch between the clonal expansion and contraction phases of a CD8؉ T cell response remain to be fully elucidated.
    [Show full text]
  • Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials
    nanomaterials Article Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials Chinatsu Nishida 1, Hiroto Izumi 2, Taisuke Tomonaga 2 , Jun-ichi Takeshita 3 , Ke-Yong Wang 4, Kei Yamasaki 1, Kazuhiro Yatera 1 and Yasuo Morimoto 2,* 1 Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan. 1-1 Iseigaoka, Yahata-nishi-ku, Kitakyushu, Fukuoka 807-8555, Japan; [email protected] (C.N.); [email protected] (K.Y.); [email protected] (K.Y.) 2 Department of Occupational Pneumology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan. 1-1 Iseigaoka, Yahata-nishi-ku, Kitakyushu, Fukuoka 807-8555, Japan; [email protected] (H.I.); [email protected] (T.T.) 3 Research Institute of Science for Safety and Sustainability, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan. 16-1 Onogawa, Tsukuba, Ibaraki 305-8569, Japan; [email protected] 4 Shared-Use Research Center, University of Occupational and Environmental Health, Japan. 1-1 Iseigaoka, Yahata-nishi-ku, Kitakyushu, Fukuoka 807-8555, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-93-691-7136 Received: 3 September 2020; Accepted: 9 October 2020; Published: 15 October 2020 Abstract: We analyzed the mRNA expression of chemokines in rat lungs following intratracheal instillation of nanomaterials in order to find useful predictive markers of the pulmonary toxicity of nanomaterials. Nickel oxide (NiO) and cerium dioxide (CeO2) as nanomaterials with high pulmonary toxicity, and titanium dioxide (TiO2) and zinc oxide (ZnO) as nanomaterials with low pulmonary toxicity, were administered into rat lungs (0.8 or 4 mg/kg BW).
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • CCL2 Inhibits the Apoptosis Program Induced by Growth Factor Deprivation, Rescuing Functional T Cells1
    The Journal of Immunology CCL2 Inhibits the Apoptosis Program Induced by Growth Factor Deprivation, Rescuing Functional T Cells1 Eva Diaz-Guerra,2 Rolando Vernal,2 M. Julieta del Prete,2 Augusto Silva, and Jose A. Garcia-Sanz3 The precise mechanisms involved in the switch between the clonal expansion and contraction phases of a CD8؉ T cell response remain to be fully elucidated. One of the mechanisms implicated in the contraction phase is cytokine deprivation, which triggers apoptosis in these cells. CCR2 chemokine receptor is up-regulated following IL-2 deprivation, and its ligand CCL2 plays an essential role preventing apoptosis induced by IL-2 withdrawal not only in CTLL2 cells, but also in mouse Ag-activated primary CD8؉ T cells because it rescued functional CD8؉ T cells from deprivation induced apoptosis, promoting proliferation in response to subsequent addition of IL-2 or to secondary antigenic challenges. Thus, up-regulation of the CCR2 upon growth factor with- drawal together with the protective effects of CCL2, represent a double-edged survival strategy, protecting cells from apoptosis and enabling them to migrate toward sites where Ag and/or growth factors are available. The Journal of Immunology, 2007, 179: 7352–7357. espite the continuous generation of T lymphocytes in the is induced by TCR stimulation of naive T cells in the absence of body, their total number is tightly regulated, implying costimulatory signals. Such T cell death can be inhibited in vivo by D that T cells disappear at about the same rate as they are inflammation and in vitro by cytokines; bacterial products promote being produced.
    [Show full text]
  • Predictive Value of Preoperative Serum CCL2, CCL18, and VEGF for the Patients with Gastric Cancer Jianghong Wu1,2†, Xiaowen Liu1,2† and Yanong Wang1,2*
    Wu et al. BMC Clinical Pathology 2013, 13:15 http://www.biomedcentral.com/1472-6890/13/15 RESEARCH ARTICLE Open Access Predictive value of preoperative serum CCL2, CCL18, and VEGF for the patients with gastric cancer Jianghong Wu1,2†, Xiaowen Liu1,2† and Yanong Wang1,2* Abstract Background: To investigate the expression of chemokine ligand 2 (CCL2), chemokine ligand 18 (CCL18), and vascular endothelial growth factor (VEGF) in peripheral blood of patients with gastric cancer and their correlation with presence of malignancy and disease progression. Methods: Sixty patients with pathological proved gastric cancer were prospectively included into study. The levels of CCL2, CCL18, and VEGF in peripheral blood were examined by enzyme-linked immunosorbentassay (ELISA). Peripheral blood from 20 healthy people was examined as control. Results: The preoperative serum levels of CCL2, CCL18 and VEGF in gastric cancer patients were significantly higher than that of controls (P <0.001, P <0.001, and P <0.001, respectively). ROC curve analysis showed that with a cut-off value of ≥1272.8, the VEGF*CCL2 predicted the presence of gastric cancer with 83% sensitivity and 80% specificity. Preoperative serum CCL2 was significantly correlated to N stage (P =0.040); CCL18 associated with N stage (P =0.002), and TNM stage (P =0.002); VEGF correlated to T stage (P =0.000), N stage (P =0.015), and TNM stage (P =0.000). Conclusion: Preoperative serum levels of CCL2 and VEGF could play a crucial role in predicting the presence and progression of gastric cancer. Keywords: Gastric cancer, Diagnosis, Biological markers Background Chemokines were a kind of low-molecular weight cy- Although the incidence of gastric cancer has been sub- tokines, which were implicated in many biological pro- stantially declining for several decades, it was still the cesses, such as migration of leukocytes, angiogenesis, fourth most common cancer and the second most fre- and tumor growth.
    [Show full text]
  • CCL2 Is a Vascular Permeability Factor Inducing CCR2-Dependent Endothelial Retraction During Lung Metastasis Marko Roblek1, Darya Protsyuk1, Paul F
    Published OnlineFirst December 14, 2018; DOI: 10.1158/1541-7786.MCR-18-0530 Signal Transduction and Functional Imaging Molecular Cancer Research CCL2 Is a Vascular Permeability Factor Inducing CCR2-Dependent Endothelial Retraction during Lung Metastasis Marko Roblek1, Darya Protsyuk1, Paul F. Becker2, Cristina Stefanescu1, Christian Gorzelanny3, Jesus F.Glaus Garzon1, Lucia Knopfova4,5, Mathias Heikenwalder2,6, Bruno Luckow7, Stefan W. Schneider3, and Lubor Borsig1 Abstract Increased levels of the chemokine CCL2 in cancer patients of vascular permeability induction was observed only in are associated with poor prognosis. Experimental evidence Ccr2ecKO mice. CCL2 stimulation of pulmonary endothe- suggests that CCL2 correlates with inflammatory monocyte lial cells resulted in increased phosphorylation of MLC2, recruitment and induction of vascular activation, but the endothelial cell retraction, and vascular leakiness that was functionality remains open. Here, we show that endothelial blocked by an addition of a CCR2 inhibitor. These data Ccr2 facilitates pulmonary metastasis using an endothelial- demonstrate that endothelial CCR2 expression is required specific Ccr2-deficient mouse model (Ccr2ecKO). Similar for tumor cell extravasation and pulmonary metastasis. levels of circulating monocytes and equal leukocyte recruit- fl/fl ment to metastatic lesions of Ccr2ecKO and Ccr2 litter- Implications: The findings provide mechanistic insight into mates were observed. The absence of endothelial Ccr2 how CCL2–CCR2 signaling in endothelial cells promotes their strongly reduced pulmonary metastasis, while the primary activation through myosin light chain phosphorylation, tumor growth was unaffected. Despite a comparable cyto- resulting in endothelial retraction and enhanced tumor cell fl/fl kine milieu in Ccr2ecKO and Ccr2 littermates the absence migration and metastasis. Introduction monocytic cells that contribute to formation of a metastatic niche (3–5).
    [Show full text]